Payment overview · 2025
General Payments
$4,913.11
212 reported records · 21 companies
Healthcare provider profile · identity verified
Lee Roy Liskey, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN FRANCISCO, CA · NPI 1609990993
Verified facts
What the public records show
CMS Open Payments records show Lee Roy Liskey, MD received $4,913.11 in general payments during 2025 across 212 reported records.
ViiV Healthcare Company accounted for 29.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Cabenuva, Creon, Dovato, Eliquis, Jardiance, Linzess, Mounjaro, Ozempic, Pifeltro, Rukobia, Serostim.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
EMD Serono, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Serostim as an associated drug or biological on 153 records involving 74 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Serostim by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 238 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Descovy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Isentress by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Pifeltro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GENOTROPIN as an associated drug or biological on 864 records involving 515 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Genotropin by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Dovato by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RUKOBIA as an associated drug or biological on 3367 records involving 1303 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Rukobia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $1,459.80 | 29.7% | 59 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $746.86 | 15.2% | 30 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $557.25 | 11.3% | 28 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $403.68 | 8.2% | 18 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $290.12 | 5.9% | 11 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $258.49 | 5.3% | 11 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $233.58 | 4.8% | 12 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $157.70 | 3.2% | 6 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $144.46 | 2.9% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $115.13 | 2.3% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $99.05 | 2.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.50 | 1.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $67.83 | 1.4% | 3 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.89 | 1.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.82 | 1.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.92 | 0.9% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.06 | 0.9% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $32.27 | 0.7% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $28.87 | 0.6% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $23.36 | 0.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.47 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,913.11 | 212 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $440.13 | 18 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $380.50 | 17 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $367.17 | 14 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $339.15 | 14 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $313.35 | 13 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $259.69 | 10 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $258.49 | 11 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $233.58 | 12 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $233.58 | 12 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $157.70 | 6 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $144.46 | 8 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $127.93 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $125.76 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $99.05 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $88.13 | 4 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $87.87 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $67.83 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $62.03 | 3 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $61.89 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.03 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.03 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.82 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $45.92 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $42.06 | 2 | 2025 |
Source payment records
|
|||||
| Serostim Normalized: serostim |
Drug | EMD Serono, Inc. | $39.28 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $32.27 | 2 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $30.43 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $28.87 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $26.23 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 238 | exact normalized | Medicare Part D |
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 69 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 54 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 84 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PIFELTRO pifeltro |
2025 | Pifeltro | 2024 | 74 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RUKOBIA rukobia |
2025 | Rukobia | 2024 | 94 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Serostim serostim |
2025 | Serostim | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| EMD Serono, Inc. Exact reporting entity; no affiliate inference |
2025 | Serostim open payments reported associated product |
CMS Open Payments — General Payments 153 supporting records · 74 recipient NPIs · example record 1236871463 |
Serostim · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
238 | 24 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
82 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
92 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | GENOTROPIN open payments reported associated product |
CMS Open Payments — General Payments 864 supporting records · 515 recipient NPIs · example record 1228794127 |
Genotropin · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 15 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
69 | 11 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | RUKOBIA open payments reported associated product |
CMS Open Payments — General Payments 3367 supporting records · 1303 recipient NPIs · example record 1189508926 |
Rukobia · 2024 Exact normalized brand match · 1 Part D row |
94 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 238 | 24 |
| Atorvastatin Calcium | Atorvastatin Calcium | 155 | 38 |
| Gabapentin | Gabapentin | 155 | 25 |
| Acyclovir | Acyclovir | 144 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 142 | 12 |
| Lisinopril | Lisinopril | 122 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 23 |
| Testosterone | Testosterone | 113 | 22 |
| Finasteride | Finasteride | 112 | 18 |
| Lorazepam | Lorazepam | 108 | 19 |
| Trazodone Hcl | Trazodone Hcl | 107 | 17 |
| Clonazepam | Clonazepam | 103 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 102 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 100 | 24 |
| Rukobia | Fostemsavir Tromethamine | 94 | suppressed |
| Metformin Hcl | Metformin Hcl | 93 | 22 |
| Isentress | Raltegravir Potassium | 92 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 86 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | suppressed |
| Jardiance | Empagliflozin | 84 | 12 |
| Descovy | Emtricitabine/Tenofov Alafenam | 82 | suppressed |
| Tivicay | Dolutegravir Sodium | 80 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 74 | 29 |
| Pifeltro | Doravirine | 74 | suppressed |
| Repatha Sureclick | Evolocumab | 71 | suppressed |
| Losartan Potassium | Losartan Potassium | 70 | 18 |
| Bupropion Xl | Bupropion Hcl | 69 | 11 |
| Dovato | Dolutegravir Sodium/Lamivudine | 69 | 11 |
| Amlodipine Besylate | Amlodipine Besylate | 63 | 16 |
| Ketoconazole | Ketoconazole | 63 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 61 | suppressed |
| Maraviroc | Maraviroc | 61 | suppressed |
| Omeprazole | Omeprazole | 58 | 13 |
| Eliquis | Apixaban | 54 | 11 |
| Tadalafil | Tadalafil | 54 | 11 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 54 | suppressed |
| Creon | Lipase/Protease/Amylase | 53 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 29 |
| Linzess | Linaclotide | 50 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | suppressed |
| Vascepa | Icosapent Ethyl | 49 | suppressed |
| Dutasteride | Dutasteride | 48 | suppressed |
| Alprazolam | Alprazolam | 46 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 20 |
| Serostim | Somatropin | 44 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 40 | 11 |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 38 | suppressed |
| Lamivudine | Lamivudine | 37 | suppressed |
| Nevirapine | Nevirapine | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 15 |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Nevirapine Er | Nevirapine | 32 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 30 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 30 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 29 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Cialis | Tadalafil | 27 | suppressed |
| Furosemide | Furosemide | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Abacavir | Abacavir Sulfate | 26 | suppressed |
| Egrifta Sv | Tesamorelin Acetate | 26 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Oxycontin | Oxycodone Hcl | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 15 |
| Etravirine | Etravirine | 21 | suppressed |
| Febuxostat | Febuxostat | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 18 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 15 |
| Famciclovir | Famciclovir | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Edurant | Rilpivirine Hcl | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Truvada | Emtricitabine/Tenofovir (Tdf) | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Bystolic | Nebivolol Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Imiquimod | Imiquimod | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Permethrin | Permethrin | 12 | suppressed |
| Selzentry | Maraviroc | 12 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 12 | suppressed |
| Ambien | Zolpidem Tartrate | 11 | suppressed |
| Androgel | Testosterone | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Genotropin | Somatropin | 11 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,913.11 · 212 records | ViiV Healthcare Company | APLENZIN, APRETUDE, Biktarvy, CABENUVA, CAPLYTA, CAPVAXIVE, CREON, Cologuard Collection Kit, DOVATO, DUPIXENT, EGRIFTA, ELIQUIS, JARDIANCE, LEQVIO, LINZESS, LOREEV XR, MOUNJARO, NURTEC ODT, NUZYRA, Ozempic, PIFELTRO, REXULTI, RUKOBIA, Rybelsus, Serostim, TROGARZO, Tlando, VIBERZI, VRAYLAR, WINREVAIR, Wegovy, XYOSTED, ZENPEP, ZEPBOUND, ZORYVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error